Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status
NCT00602667 Phase I Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting
NCT00669669 Phase Ib/II O6-benzylguanine Carmustine + Filgrastim + Plerixafor + Temozolomide Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas Active, not recruiting
NCT00998010 Phase II Bortezomib + Temozolomide Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed
NCT01130077 Phase I Poly ICLC A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas Recruiting
NCT01149850 Phase II Bevacizumab + Temozolomide Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma Active, not recruiting
NCT01260506 Phase Ib/II Bevacizumab + VB-111 Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Completed
NCT01266031 Phase Ib/II Bevacizumab + Vorinostat Bevacizumab Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma Completed
NCT01339039 Phase I Bevacizumab + Plerixafor Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Terminated
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting
NCT01430351 Phase I Metformin + Temozolomide Mefloquine + Temozolomide Memantine + Metformin + Temozolomide Mefloquine + Memantine + Temozolomide Mefloquine + Memantine + Metformin + Temozolomide Temozolomide Mefloquine + Metformin + Temozolomide Memantine + Temozolomide Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy Active, not recruiting
NCT01434602 Phase Ib/II Everolimus + Sorafenib Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas Recruiting
NCT01435395 Phase I Bevacizumab + Bortezomib + Temozolomide Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme Completed
NCT01591577 Phase II Lapatinib + Temozolomide Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme Active, not recruiting
NCT01721577 Phase Ib/II AXL1717 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status
NCT01730950 Phase II Bevacizumab Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma Active, not recruiting
NCT01753713 Phase II Dovitinib Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Completed
NCT01790503 Phase Ib/II Pexidartinib Temozolomide A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed
NCT01837862 Phase Ib/II Carboplatin + Mebendazole + Temozolomide + Vincristine Sulfate Bevacizumab + Irinotecan + Mebendazole A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting
NCT01894061 Phase II Bevacizumab NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Completed
NCT01903330 Phase II Bevacizumab Cyclophosphamide Sargramostim ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme Recruiting
NCT01931098 Phase II Pazopanib + Topotecan Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM) Completed
NCT01977677 Phase Ib/II Temozolomide Plerixafor Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
NCT01989052 Phase Ib/II Lomustine Carboxyamidotriazole Orotate Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Terminated
NCT02052648 Phase Ib/II Temozolomide Indoximod Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Completed
NCT02078648 Phase Ib/II SL-701 Poly ICLC Bevacizumab Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Completed
NCT02101905 Phase I Lapatinib Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Active, not recruiting
NCT02133183 Phase I Sapanisertib TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma Active, not recruiting
NCT02137759 Phase II Vorinostat Temozolomide MRSI to Predict Response to RT/TMZ and Vorinostat in GBM Active, not recruiting
NCT02152982 Phase II Veliparib Temozolomide Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Active, not recruiting
NCT02197169 Phase I DNX-2401 DNX-2401 + Interferon gamma DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I) Completed
NCT02238496 Phase II Perifosine + Temsirolimus Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Active, not recruiting
NCT02287428 Phase I NeoVax Pembrolizumab Temozolomide NeoVax + Pembrolizumab + Temozolomide NeoVax + Pembrolizumab Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM Recruiting
NCT02311920 Phase I Temozolomide Nivolumab Ipilimumab Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Active, not recruiting
NCT02337491 Phase II Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab +/- Bevacizumab for Recurrent GBM Completed
NCT02340156 Phase II SGT-53 Temozolomide Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma Terminated
NCT02386826 Phase I Bevacizumab + Capmatinib INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Active, not recruiting
NCT02521090 Phase Ib/II EGFRBi-armed autologous activated T cells EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma Withdrawn
NCT02607124 Phase Ib/II Ribociclib Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Unknown status
NCT02626364 Phase II Crenolanib Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification Completed
NCT02648633 Phase I Nivolumab + Valproic acid Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma Terminated
NCT02658981 Phase I Relatlimab Urelumab Nivolumab + Urelumab Nivolumab + Relatlimab Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) Active, not recruiting
NCT02661282 Phase Ib/II Autologous CMV-specific CTLs + Temozolomide Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Active, not recruiting
NCT02743078 Phase II Bevacizumab Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Terminated
NCT02798406 Phase II DNX-2401 + Pembrolizumab Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE) Active, not recruiting
NCT02852655 Phase 0 Pembrolizumab A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Active, not recruiting
NCT02871843 Phase I RRx-001 + Temozolomide Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1) Active, not recruiting
NCT02942264 Phase Ib/II Zotiraciclib Temozolomide + Zotiraciclib TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma Completed
NCT02977780 Phase II CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) Recruiting
NCT03027388 Phase I LB-100 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Recruiting
NCT03107780 Phase I KRT-232 Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Recruiting
NCT03139916 Phase II Bavituximab + Temozolomide Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma Active, not recruiting
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting
NCT03174197 Phase Ib/II Atezolizumab + Temozolomide Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM) Active, not recruiting
NCT03197506 Phase II Pembrolizumab + Temozolomide Pembrolizumab Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma Suspended
NCT03277638 Phase Ib/II Pembrolizumab Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma Recruiting
NCT03344250 Phase I EGFRBi-armed autologous activated T cells Phase I EGFR BATs in Newly Diagnosed Glioblastoma Recruiting
NCT03367715 Phase II Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma Recruiting
NCT03426891 Phase I Pembrolizumab + Temozolomide + Vorinostat Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Recruiting
NCT03452930 Phase I Tinostamustine Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Recruiting
NCT03532295 Phase II Bevacizumab + Epacadostat + Radiotherapy + Retifanlimab Bevacizumab + Radiotherapy + Retifanlimab INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas Recruiting
NCT03641326 Phase II Sunitinib Sunitinib in Sarcomas of the Central Nervous System Recruiting
NCT03657576 Phase I C134-HSV-1 Trial of C134 in Patients With Recurrent GBM (C134-HSV-1) Recruiting
NCT03681028 Phase I Feasibility of Individualized Therapy for Recurrent GBM Active, not recruiting
NCT03707457 Phase I Ipilimumab + Nivolumab MK-4166 + Nivolumab Epacadostat + Nivolumab Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma Terminated
NCT03856099 Phase II Tanibirumab TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab Recruiting
NCT03896568 Phase I DNX-2401 Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Recruiting
NCT03961971 Phase I Sabatolimab + Spartalizumab Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM Recruiting
NCT03965494 Phase I Bemcentinib AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery Recruiting
NCT03970447 Phase II Lomustine Regorafenib Temozolomide A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) Recruiting
NCT04013672 Phase II Montanide ISA 51 + Pembrolizumab + Sargramostim + SurVaxM Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence Recruiting
NCT04051606 Phase II Regorafenib Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma Recruiting
NCT04195139 Phase II Nivolumab + Temozolomide Temozolomide Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NUTMEG) Recruiting
NCT04216329 Phase I Selinexor + Temozolomide Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Recruiting
NCT04225039 Phase II INCAGN01876 + Retifanlimab Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma Recruiting
NCT04254419 Phase I Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas Not yet recruiting
NCT04396860 Phase II Temozolomide Ipilimumab + Nivolumab Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Recruiting
NCT04406272 Phase II Bevacizumab + VB-111 VB-111 in Surgically Accessible Recurrent/Progressive GBM Recruiting
NCT04555577 Phase I MSC2490484A Temozolomide Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma Not yet recruiting